Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will present at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology in February 2022. Notable presentations include a workshop on inner ear therapies where Bonnie Jacques, Ph.D., will discuss intratympanic drug delivery.

Otonomy's poster presentations will feature critical research on OTO-825 gene therapy and its impact on hearing loss, alongside other collaborative studies focused on otoprotection and hair cell regeneration.

Positive

• Participation in a prominent conference enhances visibility.
• Presentation of innovative research on OTO-825 gene therapy.
• Collaboration with other researchers may lead to new therapeutic insights.

Negative

• None.

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February.

Otonomy is participating in a workshop entitled “Translational delivery approaches for inner ear therapies” that will be held from 11 a.m. to 1 p.m. ET on February 11. The Otonomy presentation topic and presenter are as follows:

• “Factors in intratympanic drug delivery for the inner ear” by Bonnie Jacques, Ph.D.
  

All other presentations are posters that will be available for registered attendees via the conference website beginning on February 1.

Poster presentations by Otonomy authors:

• “OTO-825 gene therapy rescues hearing loss and cochlear degeneration in a clinically relevant inducible mouse model of GJB2 congenital hearing loss” by Mathur et al. (poster #323)
  
  
• “AAV-mediated gene therapy with OTO-825 rescues hearing loss and cochlear degeneration in a clinically relevant tissue specific mouse model of GJB2 congenital hearing loss” by Uribe et al. (poster #330)
  
  
• “Identification and characterization of a novel therapeutic class of otoprotectants for the prevention of cisplatin-induced hearing loss”, poster by Fernandez et al. (poster #527)
  

Poster presentations by Otonomy collaborators:

• “The Trkb-selective agonist monoclonal antibody M3 promotes in vivo spiral ganglion cell survival in deafened guinea pigs” by Vink et al. (poster #514)
  
  
• “Development of an enhanced screening assay to distinguish between hair cell regeneration and otoprotection” by Singh et al. (poster #751)
  

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What is the significance of Otonomy's presentations at the ARO MidWinter Meeting?

Otonomy's presentations showcase their ongoing research in innovative therapeutics for hearing loss, particularly the OTO-825 gene therapy.

When will Otonomy present their findings?

Otonomy will present at the ARO MidWinter Meeting held virtually on February 11, 2022.

What topics will Otonomy cover during their presentations?

Otonomy's presentations will cover intratympanic drug delivery and findings related to OTO-825 gene therapy aimed at addressing hearing loss.

Where can I find Otonomy's poster presentations?

Otonomy's poster presentations will be available for registered attendees via the conference website starting February 1, 2022.

What is Otonomy's focus as a biopharmaceutical company?

Otonomy is dedicated to developing innovative therapeutics for neurotology, particularly in treating hearing loss and tinnitus.